On this page
Oxycodone and Acetaminophen
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Acetaminophen | 300 mg/1 | 313782 | View |
| Acetaminophen | 325 mg/1 | 313782 | View |
| Oxycodone | 10 mg/1 | 1049214 | View |
| Oxycodone | 2.5 mg/1 | 1049214 | View |
| Oxycodone | 5 mg/1 | 1049214 | View |
| Oxycodone | 7.5 mg/1 | 1049214 | View |
| Oxycodone Hydrochloride | 10 mg/1 | 1049621 | View |
| Oxycodone Hydrochloride | 2.5 mg/1 | 1049621 | View |
| Oxycodone Hydrochloride | 5 mg/1 | 1049621 | View |
| Oxycodone Hydrochloride | 7.5 mg/1 | 1049621 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Full Opioid Agonists [MoA] | MoA | All 74 members |
| Opioid Agonist [EPC] | EPC | All 109 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 207419-001 | OXYCODONE AND ACETAMINOPHEN | TABLET | ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE | Prescription | AA | ||
| 207419-002 | OXYCODONE AND ACETAMINOPHEN | TABLET | ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE | Prescription | AA | ||
| 207419-003 | OXYCODONE AND ACETAMINOPHEN | TABLET | ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE | Prescription | AA | ||
| 207419-004 | OXYCODONE AND ACETAMINOPHEN | TABLET | ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE | Prescription | AA |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 21 | REMS | Approved | June 18, 2026 | — |
| Supplement | 20 | Labeling | Approved | December 22, 2025 | Standard |
| Supplement | 14 | REMS | Approved | October 31, 2024 | — |
| Supplement | 15 | Labeling | Approved | August 22, 2024 | Standard |
| Supplement | 13 | Labeling | Approved | August 22, 2024 | Standard |
| Supplement | 12 | Labeling | Approved | December 15, 2023 | Standard |
| Supplement | 11 | Labeling | Approved | December 15, 2023 | Standard |
| Supplement | 10 | Labeling | Approved | March 4, 2021 | Standard |
| Supplement | 6 | Labeling | Approved | October 7, 2019 | Standard |
| Supplement | 3 | Manufacturing (CMC) | Approved | October 29, 2018 | Unknown |
| Supplement | 4 | Labeling | Approved | September 20, 2018 | Standard |
| Supplement | 2 | REMS | Approved | September 18, 2018 | — |
| Original application | 1 | Approved | March 22, 2017 | Standard |
Review documents
- 0 · Original application · November 8, 2023
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260615). This is the manufacturer's labelling text, not a summary and not advice.
Boxed Warning
openFDA Drug LabelingWARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME, CYTOCHROME P450 3A4 INTERACTION; HEPATOTOXICITY, and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone and acetaminophen tablets expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing oxycodone and acetaminophen tablets, and monitor all patients regularly for the development of these behaviors and conditions [see WARNINGS ]. Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS): To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a REMS for these products [see Warnings ] . Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to complete a REMS-compliant education program, counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products, emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist, and consider other tools to improve patient, household, and community safety. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of oxycodone and acetaminophen tablets. Monitor for respiratory depression, especially during initiation of oxycodone and acetaminophen tablets or following a dose increase [see WARNINGS ]. Accidental Ingestion Accidental ingestion of oxycodone and acetaminophen tablets, especially by children, can result in fatal overdose of oxycodone and acetaminophen tablets [see WARNINGS ]. Neonatal Opioid Withdrawal Syndrome Prolonged use of oxycodone and acetaminophen tablets during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see WARNINGS ]. Cytochrome P450 3A4 Interaction The concomitant use of oxycodone and acetaminophen tablets with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving oxycodone and acetaminophen tablets and any CYP3A4 inhibitor or inducer [see CLINICAL PHARMACOLOGY , WARNINGS , PRECAUTIONS; Drug Interactions ]. Hepatotoxicity Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 mg per day, and often involve more than one acetaminophen-containing product. Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death [see WARNINGS , PRECAUTIONS; Drug Interactions ]. Reserve concomitant prescribing of oxycodone and acetaminophen tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options …
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Oxycodone and Acetaminophen Tablets, USP are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosage or duration [see WARNINGS ], reserve oxycodone and acetaminophen tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia Oxycodone and acetaminophen tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Important Dosage and Administration Instructions Oxycodone and acetaminophen tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals [see WARNINGS ] . Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of oxycodone and acetaminophen tablets for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available. There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient’s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse [see WARNINGS ] . Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with oxycodone and acetaminophen tablets. Consider this risk when selecting an initial dose and when making dose adjustments [see WARNINGS ]. Patient Access to an Opioid Overdose Reversal Agent for the Emergency Treatment of Opioid Overdose Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene). Discuss the importance of having access to an opioid overdose reversal agent, especially if the patient has risk factors for overdose (e.g., concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose) or if there are household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose. The presence of risk factors for overdose should not prevent the management of pain in any patient [see WARNINGS; Addiction, Abuse, and Misuse ; Life-Threatening Respiratory Depression ; Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants ]. Discuss the options for obtaining an opioid overdose reversal agent (e.g., prescription, over-the-counter, or as part of a community-based program). There are important differences among the opioid overdose reversal agents, such as route of administration, product strength, approved patient age range, and pharmacokinetics. Be familiar with these differences, as outlined in the approved labeling for those products, prior to recommending or prescribing such an agent. Initial Dosage Use of Oxycodone and Acetaminophen Tablets as the First Opioid Analgesic Initiate treatment with oxycodone and acetaminophen tablets using oxycodone and acetaminophen tablets 2.5 mg/325 mg tablets in a dosing range of 1 to 2 tablets every 6 hours as needed for pain, at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient’s response to their initial dose of oxycodone and acetaminophen tablets. The total daily dose of acetaminophen should not exceed 4 grams. Strength Usual Adult Dosage Maximal Daily Dose Oxycodone and Acetaminophen Tablets 5 mg/325 mg 1 tablet every 6 hours as needed for pain 12 Tablets Oxycodone and Acetaminophen Tablets 7.5 mg/325 mg 1 tablet every 6 hours as needed for pain 8 Tablets Oxycodone and Acetaminophen Tablets 10 mg/325 mg 1 tablet every 6 hours as needed for pain 6 Tablets Conversion from Oxycodone and Acetaminophen Tablets to Extended-Release Oxycodone The relative bioavailability of oxycodone and acetaminophen tablets compared to extended-release oxycodo …
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Oxycodone and acetaminophen tablets should not be administered to patients with known hypersensitivity to oxycodone, acetaminophen, or any other component of this product. Oxycodone is contraindicated in any situation where opioids are contraindicated including patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment) and patients with acute or severe bronchial asthma or hypercarbia. Oxycodone is contraindicated in the setting of suspected or known paralytic ileus.
Warnings
openFDA Drug LabelingWARNINGS Addiction, Abuse, and Misuse Oxycodone and acetaminophen tablets contain oxycodone, a Schedule II controlled substance. As an opioid, oxycodone and acetaminophen tablets expose users to the risks of addiction, abuse, and misuse [see DRUG ABUSE AND DEPENDENCE ]. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed oxycodone and acetaminophen tablets. Addiction can occur at recommended dosages and if the drug is misused or abused. Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing oxycodone and acetaminophen tablets, and monitor all patients receiving oxycodone and acetaminophen tablets for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as oxycodone and acetaminophen tablets, but use in such patients necessitates intensive counseling about the risks and proper use of oxycodone and acetaminophen tablets along with intensive monitoring for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see WARNINGS, Life-Threatening Respiratory Depression ; DOSAGE AND ADMINISTRATION, Patient Access to Naloxone for The Emergency Treatment of Opioid Overdose ] . Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion. Consider these risks when prescribing or dispensing oxycodone and acetaminophen tablets. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drug [see PRECAUTIONS; Information for Patients/Caregivers ]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product. Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to do all of the following: Complete a REMS-compliant education program offered by an accredited provider of continuing education (CE) or another education program that includes all the elements of the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain. Discuss the safe use, serious risks, and proper storage and disposal of opioid analgesics with patients and/or their caregivers every time these medicines are prescribed. The Patient Counseling Guide (PCG) can be obtained at this link: www.fda.gov/OpioidAnalgesicREMSPCG . Emphasize to patients and their caregivers the importance of reading the Medication Guide that they will receive from their pharmacist every time an opioid analgesic is dispensed to them. Consider using other tools to improve patient, household, and community safety, such as patient-prescriber agreements that reinforce patient-prescriber responsibilities. To obtain further information on the opioid analgesic REMS and for a list of accredited REMS CME/CE, call 1-800-503-0784, or log on to www.opioidanalgesicrems.com . The FDA Blueprint can be found at www.fda.gov/OpioidAnalgesicREMSBlueprint . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even …
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following adverse reactions have been identified during post approval use of oxycodone and acetaminophen tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Serious adverse reactions that may be associated with oxycodone and acetaminophen use include respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and shock [see OVERDOSAGE ] . The most frequently observed non-serious adverse reactions include lightheadedness, dizziness, drowsiness or sedation, nausea, and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include euphoria, dysphoria, constipation, and pruritus. Hypersensitivity reactions may include: Skin eruptions, urticarial, erythematous skin reactions. Hematologic reactions may include: thrombocytopenia, neutropenia, pancytopenia, hemolytic anemia. Rare cases of agranulocytosis has likewise been associated with acetaminophen use. In high doses, the most serious adverse effect is a dose-dependent, potentially fatal hepatic necrosis. Renal tubular necrosis and hypoglycemic coma also may occur. Other adverse reactions obtained from postmarketing experiences with oxycodone and acetaminophen are listed by organ system and in decreasing order of severity and/or frequency as follows: Body as a Whole: Anaphylactoid reaction, allergic reaction, malaise, asthenia, fatigue, chest pain, fever, hypothermia, thirst, headache, increased sweating, accidental overdose, non-accidental overdose Cardiovascular: Hypotension, hypertension, tachycardia, orthostatic hypotension, bradycardia, palpitations, dysrhythmias Central and Peripheral Nervous System: Stupor, tremor, paraesthesia, hypoaesthesia, lethargy, seizures, anxiety, mental impairment, agitation, cerebral edema, confusion, dizziness Fluid and Electrolyte: Dehydration, hyperkalemia, metabolic acidosis, respiratory alkalosis Gastrointestinal: Dyspepsia, taste disturbances, abdominal pain, abdominal distention, sweating increased, diarrhea, dry mouth, flatulence, gastrointestinal disorder, nausea, vomiting, pancreatitis, intestinal obstruction, ileus Hepatic: Transient elevations of hepatic enzymes, increase in bilirubin, hepatitis, hepatic failure, jaundice, hepatotoxicity, hepatic disorder Hearing and Vestibular: Hearing loss, tinnitus Hematologic: Thrombocytopenia Hypersensitivity: Acute anaphylaxis, angioedema, asthma, bronchospasm, laryngeal edema, urticaria, anaphylactoid reaction Metabolic and Nutritional: Hypoglycemia, hyperglycemia, acidosis, alkalosis Musculoskeletal: Myalgia, rhabdomyolysis Ocular: Miosis, visual disturbances, red eye Psychiatric: Drug dependence, drug abuse, insomnia, confusion, anxiety, agitation, depressed level of consciousness, nervousness, hallucination, somnolence, depression, suicide Respiratory System: Bronchospasm, dyspnea, hyperpnea, pulmonary edema, tachypnea, aspiration, hypoventilation, laryngeal edema Skin and Appendages: Erythema, urticaria, rash, flushing Urogenital: Interstitial nephritis, papillary necrosis, proteinuria, renal insufficiency and failure, urinary retention Serotonin syndrome : Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs. Adrenal insufficiency : Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Anaphylaxis : Anaphylaxis has been reported with ingredients contained in oxycodone and acetaminophen tablets. Androgen deficiency : Cases of androgen deficiency have occurred with use of opioids for an extended period of time. Hyperalgesia and Allodynia : Cases of hyperalgesia and allodynia have been rep …
Drug Interactions
openFDA Drug LabelingDRUG INTERACTIONS Inhibitors of CYP3A4 and CYP2D6 The concomitant use of Oxycodone and Acetaminophen Tablets and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), and protease inhibitors (e.g., ritonavir), can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of Oxycodone and Acetaminophen Tablets and CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of Oxycodone and Acetaminophen Tablets are achieved [see Warnings]. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease [see Clinical Pharmacology] , resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to Oxycodone and Acetaminophen Tablets. If concomitant use is necessary, consider dosage reduction of Oxycodone and Acetaminophen Tablets until stable drug effects are achieved. Evaluate patients at frequent intervals for respiratory depression and sedation. If a CYP3A4 inhibitor is discontinued, consider increasing the Oxycodone and Acetaminophen Tablets dosage until stable drug effects are achieved. Evaluate for signs of opioid withdrawal. Inducers of CYP3A4 The concomitant use of Oxycodone and Acetaminophen Tablets and CYP3A4 inducers, such as rifampin, carbamazepine, and phenytoin, can decrease the plasma concentration of oxycodone [see Clinical Pharmacology] , resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to Oxycodone and Acetaminophen Tablets [see Warnings]. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the oxycodone plasma concentration will increase [see Clinical Pharmacology] , which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression. If concomitant use is necessary, consider increasing the Oxycodone and Acetaminophen Tablets dosage until stable drug effects are achieved. Evaluate for sign of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider Oxycodone and Acetaminophen Tablets dosage reduction and evaluate patients at frequent intervals for signs of respiratory depression and sedation. Benzodiazepines and Other Central Nervous System (CNS) Depressants Due to additive pharmacologic effect, the concomitant use of benzodiazepines and other CNS depressants such as benzodiazepines and other sedative hypnotics, anxiolytics, and tranquilizers, muscle relaxants, general anesthetics, antipsychotics, and other opioids, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose [see Warnings]. Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome. [see Precautions; Information for Patients/ …
Mechanism of Action
openFDA Drug LabelingMechanism of Action Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions.
Description
openFDA Drug LabelingDESCRIPTION Oxycodone Hydrochloride and Acetaminophen is available in tablets for oral administration. Each tablet for oral administration, contains Oxycodone Hydrochloride and Acetaminophen in the following strengths: Oxycodone Hydrochloride, USP.................................................................. 2.5 mg* (*2.5 mg Oxycodone Hydrochloride is equivalent to 2.2409 mg of Oxycodone) Acetaminophen, USP...................................................................................... 325 mg Oxycodone Hydrochloride, USP.................................................................. 5 mg* (*5 mg Oxycodone Hydrochloride is equivalent to 4.4815 mg of Oxycodone) Acetaminophen, USP...................................................................................... 325 mg Oxycodone Hydrochloride, USP.................................................................. 7.5 mg* (*7.5 mg Oxycodone Hydrochloride is equivalent to 6.7228 mg of Oxycodone) Acetaminophen, USP...................................................................................... 325 mg Oxycodone Hydrochloride, USP.................................................................. 10 mg* (*10 mg Oxycodone Hydrochloride is equivalent to 8.9637 mg of Oxycodone) Acetaminophen, USP...................................................................................... 325 mg All Strengths of Oxycodone and Acetaminophen Tablets also contains the following inactive ingredients: Colloidal silicon dioxide, povidone, cross-linked povidone, corn starch, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, and stearic acid. Oxycodone Hydrochloride and Acetaminophen Tablets contain oxycodone, 14-hydroxydihydrocodeinone, a semisynthetic opioid analgesic which occurs as a white to off-white fine crystalline powder. The molecular formula for oxycodone hydrochloride is C 18 H 21 NO 4 ∙ HCl and the molecular weight is 351.82. It is derived from the opium alkaloid, thebaine, and may be represented by the following structural formula: C 18 H 21 NO 4 ·HCl MW 351.82 Oxycodone and Acetaminophen Tablets contain acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, free flowing granules. The molecular formula for acetaminophen is C 8 H 9 NO 2 and the molecular weight is 151.16. It may be represented by the following structural formula: C 8 H 9 NO 2 MW 151.16 oxy-structure apap-structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Following an acute overdosage, toxicity may result from the oxycodone or the acetaminophen. Clinical Presentation Oxycodone Acute overdosage with oxycodone can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, hypoglycemia, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations [ see CLINCAL PHARMACOLOGY ] . Toxic leukoencephalopathy has been reported after opioid overdose and can present hours, days, or weeks after apparent recovery from the initial intoxication. Acetaminophen Dose-dependent potentially fatal hepatic necrosis is the most serious adverse effect of acetaminophen overdosage. Renal tubular necrosis, hypoglycemic coma, and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis, and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion. Treatment of Overdose Oxycodone In case of overdose, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support measures. For clinically significant respiratory or circulatory depression secondary to opioid overdose, administer an opioid overdose reversal agent such as naloxone or nalmefene. Because the duration of opioid reversal is expected to be less than the duration of action of oxycodone in oxycodone and acetaminophen tablets, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to an opioid antagonist overdose reversal agent is suboptimal or only brief in nature, administer additional reversal agent antagonist as directed by the product’s prescribing information. In an individual physically dependent on opioids, administration of the recommended usual dosage of the antagonist opioid overdose reversal agent will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist reversal agent administered. If a decision is made to treat serious respiratory depression in the physically-dependent patient, administration of the antagonist reversal agent should be initiated begin with care and by titration with smaller than usual doses of the antagonist reversal agent. Acetaminophen Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration. Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Oxycodone and Acetaminophen Tablets, USP are supplied as follows: 2.5 mg/325 mg White to Off-white color capsule shaped tablets debossed with ‘T 191’ on one side and plain on other side. Bottles of 30 NDC 76420-320-30 (repackaged from NDC 31722-948-XX) Bottles of 60 NDC 76420-320-60 (repackaged from NDC 31722-948-XX) Bottles of 90 NDC 76420-320-90 (repackaged from NDC 31722-948-XX) Bottles of 100 NDC 76420-320-01 (relabeled from NDC 31722-948-01) Bottles of 500 NDC 76420-320-05 (relabeled from NDC 31722-948-05) 5 mg/325 mg White to off-white color round, biconvex tablets having break line on one side and debossed with ‘T 192’ on other side. Bottles of 30 NDC 76420-321-30 (repackaged from NDC 31722-949-XX) Bottles of 60 NDC 76420-321-60 (repackaged from NDC 31722-949-XX) Bottles of 90 NDC 76420-321-90 (repackaged from NDC 31722-949-XX) Bottles of 100 NDC 76420-321-01 (relabeled from NDC 31722-949-01) Bottles of 500 NDC 76420-321-05 (relabeled from NDC 31722-949-05) 7.5 mg/325 mg White to Off-white color capsule shaped tablets debossed with ‘T 193’ on one side and plain on other side. Bottles of 30 NDC 76420-322-30 (repackaged from NDC 31722-950-XX) Bottles of 60 NDC 76420-322-60 (repackaged from NDC 31722-950-XX) Bottles of 90 NDC 76420-322-90 (repackaged from NDC 31722-950-XX) Bottles of 100 NDC 76420-322-01 (relabeled from NDC 31722-950-01) Bottles of 500 NDC 76420-322-05 (relabeled from NDC 31722-950-05) 10 mg/325 mg White to off-white color capsule shaped tablets debossed with ‘T 194’ on one side and plain on other side. Bottles of 30 NDC 76420-323-30 (repackaged from NDC 31722-951-XX) Bottles of 60 NDC 76420-323-60 (repackaged from NDC 31722-951-XX) Bottles of 90 NDC 76420-323-90 (repackaged from NDC 31722-951-XX) Bottles of 100 NDC 76420-323-01 (relabeled from NDC 31722-951-01) Bottles of 500 NDC 76420-323-05 (relabeled from NDC 31722-951-05) Store at 20° to 25°C (68° to 77°F). [see USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP. Store Oxycodone and Acetaminophen Tablets securely and dispose of properly [see Precautions/Information for Patients]. Relabeled and Repackaged by: Enovachem PHARMACEUTICALS Torrance, CA 90501
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: ACETAMINOPHEN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | January 14, 2026 | SpecGx, LLC | Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets. | Ongoing |
| Class II | January 14, 2026 | SpecGx, LLC | Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets. | Ongoing |
| Class II | April 22, 2020 | Aurobindo Pharma USA Inc. | CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed | Terminated |
| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 47781-196-01 | 47781-196 | Alvogen, Inc. | 100 TABLET in 1 BOTTLE (47781-196-01) | March 9, 2016 |
| 47781-196-05 | 47781-196 | Alvogen, Inc. | 500 TABLET in 1 BOTTLE (47781-196-05) | March 9, 2016 |
| 47781-229-01 | 47781-229 | Alvogen, Inc. | 100 TABLET in 1 BOTTLE (47781-229-01) | January 17, 2012 |
| 47781-229-05 | 47781-229 | Alvogen, Inc. | 500 TABLET in 1 BOTTLE (47781-229-05) | January 17, 2012 |
| 47781-230-01 | 47781-230 | Alvogen, Inc. | 100 TABLET in 1 BOTTLE (47781-230-01) | January 17, 2012 |
| 47781-230-05 | 47781-230 | Alvogen, Inc. | 500 TABLET in 1 BOTTLE (47781-230-05) | January 17, 2012 |
| 47781-230-63 | 47781-230 | Alvogen, Inc. | 250 TABLET in 1 BOTTLE (47781-230-63) | January 17, 2012 |
| 60687-642-01 | 60687-642 | American Health Packaging | 100 BLISTER PACK in 1 CARTON (60687-642-01) / 1 TABLET in 1 BLISTER PACK (60687-642-11) | January 4, 2022 |
| 68084-699-01 | 68084-699 | American Health Packaging | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-699-01) / 1 TABLET in 1 BLISTER PACK (68084-699-11) | June 6, 2014 |
| 68084-710-01 | 68084-710 | American Health Packaging | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (68084-710-01) / 1 TABLET in 1 BLISTER PACK (68084-710-11) | June 4, 2014 |
| 65162-207-03 | 65162-207 | Amneal Pharmaceuticals LLC | 30 TABLET in 1 BOTTLE (65162-207-03) | November 1, 2013 |
| 65162-207-10 | 65162-207 | Amneal Pharmaceuticals LLC | 100 TABLET in 1 BOTTLE (65162-207-10) | November 1, 2013 |
| 65162-207-50 | 65162-207 | Amneal Pharmaceuticals LLC | 500 TABLET in 1 BOTTLE (65162-207-50) | November 1, 2013 |
| 53746-203-01 | 53746-203 | Amneal Pharmaceuticals of New York LLC | 100 TABLET in 1 BOTTLE (53746-203-01) | November 27, 2007 |
| 53746-203-05 | 53746-203 | Amneal Pharmaceuticals of New York LLC | 500 TABLET in 1 BOTTLE (53746-203-05) | November 27, 2007 |
| 53746-204-01 | 53746-204 | Amneal Pharmaceuticals of New York LLC | 100 TABLET in 1 BOTTLE (53746-204-01) | November 27, 2007 |
| 53746-204-05 | 53746-204 | Amneal Pharmaceuticals of New York LLC | 500 TABLET in 1 BOTTLE (53746-204-05) | November 27, 2007 |
| 76420-136-30 | 76420-136 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (76420-136-30) | August 28, 2021 |
| 76420-209-01 | 76420-209 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE, PLASTIC (76420-209-01) | May 5, 2022 |
| 76420-209-30 | 76420-209 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE, PLASTIC (76420-209-30) | May 5, 2022 |
| 76420-209-60 | 76420-209 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE, PLASTIC (76420-209-60) | May 5, 2022 |
| 76420-209-90 | 76420-209 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE, PLASTIC (76420-209-90) | May 5, 2022 |
| 76420-320-01 | 76420-320 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (76420-320-01) | April 15, 2025 |
| 76420-320-05 | 76420-320 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE (76420-320-05) | April 15, 2025 |
| 76420-320-30 | 76420-320 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (76420-320-30) | April 15, 2025 |
| 76420-320-60 | 76420-320 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (76420-320-60) | April 15, 2025 |
| 76420-320-90 | 76420-320 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (76420-320-90) | April 15, 2025 |
| 76420-321-01 | 76420-321 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (76420-321-01) | April 15, 2025 |
| 76420-321-05 | 76420-321 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE (76420-321-05) | April 15, 2025 |
| 76420-321-30 | 76420-321 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (76420-321-30) | April 15, 2025 |
| 76420-321-60 | 76420-321 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (76420-321-60) | April 15, 2025 |
| 76420-321-90 | 76420-321 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (76420-321-90) | April 15, 2025 |
| 76420-322-01 | 76420-322 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (76420-322-01) | April 15, 2025 |
| 76420-322-05 | 76420-322 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE (76420-322-05) | April 15, 2025 |
| 76420-322-30 | 76420-322 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (76420-322-30) | April 15, 2025 |
| 76420-322-60 | 76420-322 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (76420-322-60) | April 15, 2025 |
| 76420-322-90 | 76420-322 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (76420-322-90) | April 15, 2025 |
| 76420-323-01 | 76420-323 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (76420-323-01) | April 15, 2025 |
| 76420-323-05 | 76420-323 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE (76420-323-05) | April 15, 2025 |
| 76420-323-30 | 76420-323 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (76420-323-30) | April 15, 2025 |
| 76420-323-60 | 76420-323 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (76420-323-60) | April 15, 2025 |
| 76420-323-90 | 76420-323 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (76420-323-90) | April 15, 2025 |
| 87063-032-01 | 87063-032 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (87063-032-01) | November 25, 2025 |
| 87063-032-05 | 87063-032 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE (87063-032-05) | November 25, 2025 |
| 87063-032-10 | 87063-032 | Asclemed USA, Inc. | 10 TABLET in 1 BOTTLE (87063-032-10) | November 25, 2025 |
| 87063-032-20 | 87063-032 | Asclemed USA, Inc. | 20 TABLET in 1 BOTTLE (87063-032-20) | November 25, 2025 |
| 87063-032-30 | 87063-032 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (87063-032-30) | November 25, 2025 |
| 87063-032-60 | 87063-032 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (87063-032-60) | November 25, 2025 |
| 87063-032-90 | 87063-032 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (87063-032-90) | November 25, 2025 |
| 87063-033-01 | 87063-033 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (87063-033-01) | November 25, 2025 |
| 87063-033-05 | 87063-033 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE (87063-033-05) | November 25, 2025 |
| 87063-033-10 | 87063-033 | Asclemed USA, Inc. | 10 TABLET in 1 BOTTLE (87063-033-10) | November 25, 2025 |
| 87063-033-20 | 87063-033 | Asclemed USA, Inc. | 20 TABLET in 1 BOTTLE (87063-033-20) | November 25, 2025 |
| 87063-033-30 | 87063-033 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (87063-033-30) | November 25, 2025 |
| 87063-033-60 | 87063-033 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (87063-033-60) | November 25, 2025 |
| 87063-033-90 | 87063-033 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (87063-033-90) | November 25, 2025 |
| 87063-034-01 | 87063-034 | Asclemed USA, Inc. | 100 TABLET in 1 BOTTLE (87063-034-01) | November 25, 2025 |
| 87063-034-05 | 87063-034 | Asclemed USA, Inc. | 500 TABLET in 1 BOTTLE (87063-034-05) | November 25, 2025 |
| 87063-034-10 | 87063-034 | Asclemed USA, Inc. | 10 TABLET in 1 BOTTLE (87063-034-10) | November 25, 2025 |
| 87063-034-20 | 87063-034 | Asclemed USA, Inc. | 20 TABLET in 1 BOTTLE (87063-034-20) | November 25, 2025 |
| 87063-034-30 | 87063-034 | Asclemed USA, Inc. | 30 TABLET in 1 BOTTLE (87063-034-30) | November 25, 2025 |
| 87063-034-60 | 87063-034 | Asclemed USA, Inc. | 60 TABLET in 1 BOTTLE (87063-034-60) | November 25, 2025 |
| 87063-034-90 | 87063-034 | Asclemed USA, Inc. | 90 TABLET in 1 BOTTLE (87063-034-90) | November 25, 2025 |
| 13107-043-01 | 13107-043 | Aurolife Pharma, LLC | 100 TABLET in 1 BOTTLE (13107-043-01) | July 15, 2013 |
| 13107-043-05 | 13107-043 | Aurolife Pharma, LLC | 500 TABLET in 1 BOTTLE (13107-043-05) | July 15, 2013 |
| 13107-043-30 | 13107-043 | Aurolife Pharma, LLC | 30 TABLET in 1 BOTTLE (13107-043-30) | July 15, 2013 |
| 13107-043-99 | 13107-043 | Aurolife Pharma, LLC | 1000 TABLET in 1 BOTTLE (13107-043-99) | July 15, 2013 |
| 13107-044-01 | 13107-044 | Aurolife Pharma, LLC | 100 TABLET in 1 BOTTLE (13107-044-01) | July 15, 2013 |
| 13107-044-05 | 13107-044 | Aurolife Pharma, LLC | 500 TABLET in 1 BOTTLE (13107-044-05) | July 15, 2013 |
| 13107-044-30 | 13107-044 | Aurolife Pharma, LLC | 30 TABLET in 1 BOTTLE (13107-044-30) | July 15, 2013 |
| 13107-044-99 | 13107-044 | Aurolife Pharma, LLC | 1000 TABLET in 1 BOTTLE (13107-044-99) | July 15, 2013 |
| 13107-045-01 | 13107-045 | Aurolife Pharma, LLC | 100 TABLET in 1 BOTTLE (13107-045-01) | July 15, 2013 |
| 13107-045-05 | 13107-045 | Aurolife Pharma, LLC | 500 TABLET in 1 BOTTLE (13107-045-05) | July 15, 2013 |
| 13107-045-30 | 13107-045 | Aurolife Pharma, LLC | 30 TABLET in 1 BOTTLE (13107-045-30) | July 15, 2013 |
| 13107-045-99 | 13107-045 | Aurolife Pharma, LLC | 1000 TABLET in 1 BOTTLE (13107-045-99) | July 15, 2013 |
| 13107-046-01 | 13107-046 | Aurolife Pharma, LLC | 100 TABLET in 1 BOTTLE (13107-046-01) | July 15, 2013 |
| 13107-046-05 | 13107-046 | Aurolife Pharma, LLC | 500 TABLET in 1 BOTTLE (13107-046-05) | July 15, 2013 |
| 13107-046-30 | 13107-046 | Aurolife Pharma, LLC | 30 TABLET in 1 BOTTLE (13107-046-30) | July 15, 2013 |
| 13107-046-99 | 13107-046 | Aurolife Pharma, LLC | 1000 TABLET in 1 BOTTLE (13107-046-99) | July 15, 2013 |
| 50268-644-15 | 50268-644 | AvPAK | 50 BLISTER PACK in 1 BOX (50268-644-15) / 1 TABLET in 1 BLISTER PACK (50268-644-11) | July 9, 2018 |
| 50268-645-15 | 50268-645 | AvPAK | 50 BLISTER PACK in 1 BOX (50268-645-15) / 1 TABLET in 1 BLISTER PACK (50268-645-11) | July 9, 2018 |
| 50268-646-15 | 50268-646 | AvPAK | 50 BLISTER PACK in 1 BOX (50268-646-15) / 1 TABLET in 1 BLISTER PACK (50268-646-11) | July 9, 2018 |
| 63629-8834-1 | 63629-8834 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (63629-8834-1) | October 6, 2021 |
| 63629-8834-2 | 63629-8834 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (63629-8834-2) | October 26, 2021 |
| 63629-8834-3 | 63629-8834 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (63629-8834-3) | October 7, 2021 |
| 63629-8834-4 | 63629-8834 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (63629-8834-4) | March 15, 2023 |
| 63629-8834-5 | 63629-8834 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (63629-8834-5) | October 6, 2021 |
| 63629-8834-6 | 63629-8834 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (63629-8834-6) | March 15, 2023 |
| 63629-8834-7 | 63629-8834 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (63629-8834-7) | March 15, 2023 |
| 63629-8834-8 | 63629-8834 | Bryant Ranch Prepack | 75 TABLET in 1 BOTTLE (63629-8834-8) | March 15, 2023 |
| 63629-8834-9 | 63629-8834 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-8834-9) | March 15, 2023 |
| 63629-8876-1 | 63629-8876 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (63629-8876-1) | October 1, 2021 |
| 63629-8888-1 | 63629-8888 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (63629-8888-1) | October 7, 2021 |
| 63629-8888-2 | 63629-8888 | Bryant Ranch Prepack | 12 TABLET in 1 BOTTLE (63629-8888-2) | March 15, 2023 |
| 63629-8888-3 | 63629-8888 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (63629-8888-3) | March 15, 2023 |
| 63629-8888-4 | 63629-8888 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (63629-8888-4) | October 26, 2021 |
| 63629-8888-5 | 63629-8888 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (63629-8888-5) | December 17, 2021 |
| 63629-8888-6 | 63629-8888 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (63629-8888-6) | June 21, 2022 |
| 63629-9501-1 | 63629-9501 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE, PLASTIC (63629-9501-1) | December 14, 2022 |
| 71335-0146-0 | 71335-0146 | Bryant Ranch Prepack | 112 TABLET in 1 BOTTLE (71335-0146-0) | January 17, 2012 |
| 71335-0146-1 | 71335-0146 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-0146-1) | January 17, 2012 |
| 71335-0146-2 | 71335-0146 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-0146-2) | January 17, 2012 |
| 71335-0146-3 | 71335-0146 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-0146-3) | January 17, 2012 |
| 71335-0146-4 | 71335-0146 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-0146-4) | January 17, 2012 |
| 71335-0146-5 | 71335-0146 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-0146-5) | January 17, 2012 |
| 71335-0146-6 | 71335-0146 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-0146-6) | January 17, 2012 |
| 71335-0146-7 | 71335-0146 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-0146-7) | January 17, 2012 |
| 71335-0146-8 | 71335-0146 | Bryant Ranch Prepack | 75 TABLET in 1 BOTTLE (71335-0146-8) | January 17, 2012 |
| 71335-0146-9 | 71335-0146 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-0146-9) | January 17, 2012 |
| 71335-0216-0 | 71335-0216 | Bryant Ranch Prepack | 25 TABLET in 1 BOTTLE (71335-0216-0) | July 25, 2016 |
| 71335-0216-1 | 71335-0216 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-0216-1) | July 25, 2016 |
| 71335-0216-2 | 71335-0216 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-0216-2) | July 25, 2016 |
| 71335-0216-3 | 71335-0216 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-0216-3) | July 25, 2016 |
| 71335-0216-4 | 71335-0216 | Bryant Ranch Prepack | 12 TABLET in 1 BOTTLE (71335-0216-4) | July 25, 2016 |
| 71335-0216-5 | 71335-0216 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-0216-5) | July 25, 2016 |
| 71335-0216-6 | 71335-0216 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-0216-6) | July 25, 2016 |
| 71335-0216-7 | 71335-0216 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-0216-7) | July 25, 2016 |
| 71335-0216-8 | 71335-0216 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-0216-8) | July 25, 2016 |
| 71335-0216-9 | 71335-0216 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-0216-9) | July 25, 2016 |
| 71335-0316-0 | 71335-0316 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-0316-0) | January 17, 2012 |
| 71335-0316-1 | 71335-0316 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-0316-1) | January 17, 2012 |
| 71335-0316-2 | 71335-0316 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-0316-2) | January 17, 2012 |
| 71335-0316-3 | 71335-0316 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-0316-3) | January 17, 2012 |
| 71335-0316-4 | 71335-0316 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-0316-4) | January 17, 2012 |
| 71335-0316-5 | 71335-0316 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-0316-5) | January 17, 2012 |
| 71335-0316-6 | 71335-0316 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-0316-6) | January 17, 2012 |
| 71335-0316-7 | 71335-0316 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-0316-7) | January 17, 2012 |
| 71335-0316-8 | 71335-0316 | Bryant Ranch Prepack | 168 TABLET in 1 BOTTLE (71335-0316-8) | January 17, 2012 |
| 71335-0316-9 | 71335-0316 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-0316-9) | January 17, 2012 |
| 71335-1036-1 | 71335-1036 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1036-1) | January 7, 2019 |
| 71335-1036-2 | 71335-1036 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1036-2) | August 9, 2024 |
| 71335-1036-3 | 71335-1036 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1036-3) | December 24, 2018 |
| 71335-1036-4 | 71335-1036 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-1036-4) | August 9, 2024 |
| 71335-1036-5 | 71335-1036 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1036-5) | December 24, 2018 |
| 71335-1036-6 | 71335-1036 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-1036-6) | August 9, 2024 |
| 71335-1036-7 | 71335-1036 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-1036-7) | August 9, 2024 |
| 71335-1036-8 | 71335-1036 | Bryant Ranch Prepack | 75 TABLET in 1 BOTTLE (71335-1036-8) | August 9, 2024 |
| 71335-1036-9 | 71335-1036 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-1036-9) | August 9, 2024 |
| 71335-1420-1 | 71335-1420 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1420-1) | April 24, 2020 |
| 71335-1420-2 | 71335-1420 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1420-2) | March 5, 2020 |
| 71335-1420-3 | 71335-1420 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1420-3) | June 22, 2020 |
| 71335-1420-4 | 71335-1420 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-1420-4) | April 3, 2024 |
| 71335-1420-5 | 71335-1420 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1420-5) | January 21, 2020 |
| 71335-1420-6 | 71335-1420 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-1420-6) | April 3, 2024 |
| 71335-1420-7 | 71335-1420 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-1420-7) | September 21, 2020 |
| 71335-1420-8 | 71335-1420 | Bryant Ranch Prepack | 75 TABLET in 1 BOTTLE (71335-1420-8) | April 3, 2024 |
| 71335-1420-9 | 71335-1420 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-1420-9) | April 3, 2024 |
| 71335-1472-0 | 71335-1472 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-1472-0) | April 3, 2024 |
| 71335-1472-1 | 71335-1472 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1472-1) | June 23, 2020 |
| 71335-1472-2 | 71335-1472 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1472-2) | March 31, 2020 |
| 71335-1472-3 | 71335-1472 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE, PLASTIC (71335-1472-3) | February 28, 2020 |
| 71335-1472-4 | 71335-1472 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1472-4) | February 14, 2020 |
| 71335-1472-5 | 71335-1472 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-1472-5) | April 3, 2024 |
| 71335-1472-6 | 71335-1472 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-1472-6) | June 22, 2020 |
| 71335-1472-7 | 71335-1472 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-1472-7) | April 3, 2024 |
| 71335-1472-8 | 71335-1472 | Bryant Ranch Prepack | 168 TABLET in 1 BOTTLE (71335-1472-8) | April 3, 2024 |
| 71335-1472-9 | 71335-1472 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-1472-9) | April 3, 2024 |
| 71335-1492-0 | 71335-1492 | Bryant Ranch Prepack | 25 TABLET in 1 BOTTLE (71335-1492-0) | April 3, 2024 |
| 71335-1492-1 | 71335-1492 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-1492-1) | December 11, 2020 |
| 71335-1492-2 | 71335-1492 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1492-2) | September 21, 2020 |
| 71335-1492-3 | 71335-1492 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-1492-3) | April 3, 2024 |
| 71335-1492-4 | 71335-1492 | Bryant Ranch Prepack | 12 TABLET in 1 BOTTLE (71335-1492-4) | March 9, 2020 |
| 71335-1492-5 | 71335-1492 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-1492-5) | March 6, 2020 |
| 71335-1492-6 | 71335-1492 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1492-6) | January 21, 2020 |
| 71335-1492-7 | 71335-1492 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1492-7) | June 11, 2020 |
| 71335-1492-8 | 71335-1492 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1492-8) | April 22, 2020 |
| 71335-1492-9 | 71335-1492 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-1492-9) | April 3, 2024 |
| 71335-1909-1 | 71335-1909 | Bryant Ranch Prepack | 21 TABLET in 1 BOTTLE, PLASTIC (71335-1909-1) | May 15, 2026 |
| 71335-1909-2 | 71335-1909 | Bryant Ranch Prepack | 36 TABLET in 1 BOTTLE, PLASTIC (71335-1909-2) | May 15, 2026 |
| 71335-1909-3 | 71335-1909 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE, PLASTIC (71335-1909-3) | May 15, 2026 |
| 71335-1909-4 | 71335-1909 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE, PLASTIC (71335-1909-4) | November 8, 2022 |
| 71335-1909-5 | 71335-1909 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE, PLASTIC (71335-1909-5) | May 15, 2026 |
| 71335-1909-6 | 71335-1909 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE, PLASTIC (71335-1909-6) | May 15, 2026 |
| 71335-1909-7 | 71335-1909 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE, PLASTIC (71335-1909-7) | May 15, 2026 |
| 71335-1909-8 | 71335-1909 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE, PLASTIC (71335-1909-8) | November 4, 2022 |
| 71335-1953-0 | 71335-1953 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-1953-0) | October 13, 2022 |
| 71335-1953-1 | 71335-1953 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1953-1) | September 29, 2021 |
| 71335-1953-2 | 71335-1953 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1953-2) | September 29, 2021 |
| 71335-1953-3 | 71335-1953 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1953-3) | September 17, 2021 |
| 71335-1953-4 | 71335-1953 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1953-4) | October 7, 2021 |
| 71335-1953-5 | 71335-1953 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-1953-5) | October 13, 2022 |
| 71335-1953-6 | 71335-1953 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-1953-6) | October 13, 2022 |
| 71335-1953-7 | 71335-1953 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-1953-7) | October 13, 2022 |
| 71335-1953-8 | 71335-1953 | Bryant Ranch Prepack | 168 TABLET in 1 BOTTLE (71335-1953-8) | October 13, 2022 |
| 71335-1953-9 | 71335-1953 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-1953-9) | October 13, 2022 |
| 71335-1959-1 | 71335-1959 | Bryant Ranch Prepack | 21 TABLET in 1 BOTTLE (71335-1959-1) | May 31, 2024 |
| 71335-1959-2 | 71335-1959 | Bryant Ranch Prepack | 36 TABLET in 1 BOTTLE (71335-1959-2) | September 30, 2021 |
| 71335-1959-3 | 71335-1959 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-1959-3) | May 31, 2024 |
| 71335-1959-4 | 71335-1959 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-1959-4) | October 26, 2021 |
| 71335-1959-5 | 71335-1959 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-1959-5) | May 31, 2024 |
| 71335-1959-6 | 71335-1959 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-1959-6) | October 7, 2021 |
| 71335-1959-7 | 71335-1959 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-1959-7) | October 26, 2021 |
| 71335-1959-8 | 71335-1959 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-1959-8) | November 10, 2021 |
| 71335-2041-0 | 71335-2041 | Bryant Ranch Prepack | 25 TABLET in 1 BOTTLE (71335-2041-0) | May 31, 2024 |
| 71335-2041-1 | 71335-2041 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-2041-1) | March 14, 2022 |
| 71335-2041-2 | 71335-2041 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-2041-2) | February 1, 2022 |
| 71335-2041-3 | 71335-2041 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-2041-3) | May 31, 2024 |
| 71335-2041-4 | 71335-2041 | Bryant Ranch Prepack | 12 TABLET in 1 BOTTLE (71335-2041-4) | May 31, 2024 |
| 71335-2041-5 | 71335-2041 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-2041-5) | March 16, 2022 |
| 71335-2041-6 | 71335-2041 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2041-6) | February 18, 2022 |
| 71335-2041-7 | 71335-2041 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2041-7) | February 10, 2022 |
| 71335-2041-8 | 71335-2041 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2041-8) | May 9, 2022 |
| 71335-2041-9 | 71335-2041 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-2041-9) | May 31, 2024 |
| 71335-2049-1 | 71335-2049 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2049-1) | February 28, 2022 |
| 71335-2049-2 | 71335-2049 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-2049-2) | February 28, 2022 |
| 71335-2049-3 | 71335-2049 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2049-3) | February 28, 2022 |
| 71335-2049-4 | 71335-2049 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-2049-4) | February 28, 2022 |
| 71335-2049-5 | 71335-2049 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2049-5) | February 28, 2022 |
| 71335-2049-6 | 71335-2049 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2049-6) | February 28, 2022 |
| 71335-2049-7 | 71335-2049 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-2049-7) | February 28, 2022 |
| 71335-2049-8 | 71335-2049 | Bryant Ranch Prepack | 75 TABLET in 1 BOTTLE (71335-2049-8) | February 28, 2022 |
| 71335-2049-9 | 71335-2049 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-2049-9) | February 28, 2022 |
| 71335-2106-1 | 71335-2106 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2106-1) | July 5, 2022 |
| 71335-2106-2 | 71335-2106 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-2106-2) | May 31, 2024 |
| 71335-2106-3 | 71335-2106 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2106-3) | July 11, 2022 |
| 71335-2106-4 | 71335-2106 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-2106-4) | May 31, 2024 |
| 71335-2106-5 | 71335-2106 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2106-5) | June 10, 2022 |
| 71335-2106-6 | 71335-2106 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2106-6) | May 31, 2024 |
| 71335-2106-7 | 71335-2106 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-2106-7) | May 31, 2024 |
| 71335-2106-8 | 71335-2106 | Bryant Ranch Prepack | 75 TABLET in 1 BOTTLE (71335-2106-8) | May 31, 2024 |
| 71335-2106-9 | 71335-2106 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-2106-9) | May 31, 2024 |
| 71335-9674-0 | 71335-9674 | Bryant Ranch Prepack | 25 TABLET in 1 BOTTLE (71335-9674-0) | April 13, 2026 |
| 71335-9674-1 | 71335-9674 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-9674-1) | August 20, 2024 |
| 71335-9674-2 | 71335-9674 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-9674-2) | April 28, 2023 |
| 71335-9674-3 | 71335-9674 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-9674-3) | April 13, 2026 |
| 71335-9674-4 | 71335-9674 | Bryant Ranch Prepack | 12 TABLET in 1 BOTTLE (71335-9674-4) | April 13, 2026 |
| 71335-9674-5 | 71335-9674 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-9674-5) | April 27, 2023 |
| 71335-9674-6 | 71335-9674 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-9674-6) | June 1, 2023 |
| 71335-9674-7 | 71335-9674 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-9674-7) | April 13, 2026 |
| 71335-9674-8 | 71335-9674 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-9674-8) | May 23, 2023 |
| 71335-9674-9 | 71335-9674 | Bryant Ranch Prepack | 84 TABLET in 1 BOTTLE (71335-9674-9) | April 13, 2026 |
| 71335-9675-1 | 71335-9675 | Bryant Ranch Prepack | 21 TABLET in 1 BOTTLE (71335-9675-1) | April 13, 2026 |
| 71335-9675-2 | 71335-9675 | Bryant Ranch Prepack | 36 TABLET in 1 BOTTLE (71335-9675-2) | April 13, 2026 |
| 71335-9675-3 | 71335-9675 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-9675-3) | April 13, 2026 |
| 71335-9675-4 | 71335-9675 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-9675-4) | April 13, 2026 |
| 71335-9675-5 | 71335-9675 | Bryant Ranch Prepack | 45 TABLET in 1 BOTTLE (71335-9675-5) | April 13, 2026 |
| 71335-9675-6 | 71335-9675 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-9675-6) | April 13, 2026 |
| 71335-9675-7 | 71335-9675 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-9675-7) | April 13, 2026 |
| 71335-9675-8 | 71335-9675 | Bryant Ranch Prepack | 120 TABLET in 1 BOTTLE (71335-9675-8) | April 13, 2026 |
| 72162-1338-3 | 72162-1338 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (72162-1338-3) | April 14, 2026 |
| 72162-1338-6 | 72162-1338 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (72162-1338-6) | April 14, 2026 |
| 72162-1338-9 | 72162-1338 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (72162-1338-9) | April 14, 2026 |
| 72162-1339-3 | 72162-1339 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE, PLASTIC (72162-1339-3) | April 3, 2026 |
| 72162-1339-5 | 72162-1339 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE, PLASTIC (72162-1339-5) | April 3, 2026 |
| 72162-1339-6 | 72162-1339 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE, PLASTIC (72162-1339-6) | April 3, 2026 |
| 72162-1339-9 | 72162-1339 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE, PLASTIC (72162-1339-9) | April 3, 2026 |
| 31722-191-01 | 31722-191 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-191-01) | April 11, 2017 |
| 31722-191-05 | 31722-191 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-191-05) | April 11, 2017 |
| 31722-192-01 | 31722-192 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-192-01) | April 11, 2017 |
| 31722-192-05 | 31722-192 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-192-05) | April 11, 2017 |
| 31722-193-01 | 31722-193 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-193-01) | April 11, 2017 |
| 31722-193-05 | 31722-193 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-193-05) | April 11, 2017 |
| 31722-194-01 | 31722-194 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-194-01) | April 11, 2017 |
| 31722-194-05 | 31722-194 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-194-05) | April 11, 2017 |
| 31722-948-01 | 31722-948 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-948-01) | March 15, 2019 |
| 31722-948-05 | 31722-948 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-948-05) | March 15, 2019 |
| 31722-949-01 | 31722-949 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-949-01) | March 15, 2019 |
| 31722-949-05 | 31722-949 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-949-05) | March 15, 2019 |
| 31722-950-01 | 31722-950 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-950-01) | March 15, 2019 |
| 31722-950-05 | 31722-950 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-950-05) | March 15, 2019 |
| 31722-951-01 | 31722-951 | Camber Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (31722-951-01) | March 15, 2019 |
| 31722-951-05 | 31722-951 | Camber Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (31722-951-05) | March 15, 2019 |
| 72189-255-30 | 72189-255 | DIRECT RX | 30 TABLET in 1 BOTTLE (72189-255-30) | August 10, 2021 |
| 72189-255-60 | 72189-255 | DIRECT RX | 60 TABLET in 1 BOTTLE (72189-255-60) | August 10, 2021 |
| 72189-256-30 | 72189-256 | DIRECT RX | 30 TABLET in 1 BOTTLE (72189-256-30) | August 10, 2021 |
| 72189-256-60 | 72189-256 | DIRECT RX | 60 TABLET in 1 BOTTLE (72189-256-60) | August 10, 2021 |
| 72189-256-72 | 72189-256 | DIRECT RX | 120 TABLET in 1 BOTTLE (72189-256-72) | August 10, 2021 |
| 61919-871-60 | 61919-871 | Direct_Rx | 60 TABLET in 1 BOTTLE (61919-871-60) | August 21, 2019 |
| 61919-871-72 | 61919-871 | Direct_Rx | 120 TABLET in 1 BOTTLE (61919-871-72) | August 21, 2019 |
| 72189-368-30 | 72189-368 | Direct_Rx | 30 TABLET in 1 BOTTLE (72189-368-30) | July 28, 2022 |
| 72189-368-60 | 72189-368 | Direct_Rx | 60 TABLET in 1 BOTTLE (72189-368-60) | July 28, 2022 |
| 72189-368-72 | 72189-368 | Direct_Rx | 120 TABLET in 1 BOTTLE (72189-368-72) | July 28, 2022 |
| 72189-368-90 | 72189-368 | Direct_Rx | 90 TABLET in 1 BOTTLE (72189-368-90) | July 28, 2022 |
| 42806-114-01 | 42806-114 | Epic Pharma, LLC | 100 TABLET in 1 BOTTLE (42806-114-01) | July 2, 2018 |
| 42806-115-01 | 42806-115 | Epic Pharma, LLC | 100 TABLET in 1 BOTTLE (42806-115-01) | July 2, 2018 |
| 42806-116-01 | 42806-116 | Epic Pharma, LLC | 100 TABLET in 1 BOTTLE (42806-116-01) | July 2, 2018 |
| 71930-045-12 | 71930-045 | Eywa Pharma Inc | 100 TABLET in 1 BOTTLE (71930-045-12) | June 1, 2019 |
| 71930-045-52 | 71930-045 | Eywa Pharma Inc | 500 TABLET in 1 BOTTLE (71930-045-52) | June 1, 2019 |
| 71930-046-12 | 71930-046 | Eywa Pharma Inc | 100 TABLET in 1 BOTTLE (71930-046-12) | June 1, 2019 |
| 71930-046-52 | 71930-046 | Eywa Pharma Inc | 500 TABLET in 1 BOTTLE (71930-046-52) | June 1, 2019 |
| 71930-047-12 | 71930-047 | Eywa Pharma Inc | 100 TABLET in 1 BOTTLE (71930-047-12) | June 1, 2019 |
| 71930-047-52 | 71930-047 | Eywa Pharma Inc | 500 TABLET in 1 BOTTLE (71930-047-52) | June 1, 2019 |
| 72887-193-03 | 72887-193 | FH2 Pharma LLC | 30 TABLET in 1 BOTTLE, PLASTIC (72887-193-03) | June 3, 2019 |
| 72887-681-03 | 72887-681 | FH2 Pharma LLC | 30 TABLET in 1 BOTTLE, PLASTIC (72887-681-03) | September 25, 2020 |
| 72887-682-03 | 72887-682 | FH2 Pharma LLC | 30 TABLET in 1 BOTTLE (72887-682-03) | March 2, 2021 |
| 72887-683-03 | 72887-683 | FH2 Pharma LLC | 30 TABLET in 1 BOTTLE, PLASTIC (72887-683-03) | September 25, 2020 |
| 70010-667-01 | 70010-667 | Granules Pharmaceuticals Inc. | 100 TABLET in 1 BOTTLE (70010-667-01) | January 1, 2022 |
| 70010-667-05 | 70010-667 | Granules Pharmaceuticals Inc. | 500 TABLET in 1 BOTTLE (70010-667-05) | January 1, 2022 |
| 70010-668-01 | 70010-668 | Granules Pharmaceuticals Inc. | 100 TABLET in 1 BOTTLE (70010-668-01) | January 1, 2022 |
| 70010-668-05 | 70010-668 | Granules Pharmaceuticals Inc. | 500 TABLET in 1 BOTTLE (70010-668-05) | January 1, 2022 |
| 70010-669-01 | 70010-669 | Granules Pharmaceuticals Inc. | 100 TABLET in 1 BOTTLE (70010-669-01) | January 1, 2022 |
| 70010-669-05 | 70010-669 | Granules Pharmaceuticals Inc. | 500 TABLET in 1 BOTTLE (70010-669-05) | January 1, 2022 |
| 70010-670-01 | 70010-670 | Granules Pharmaceuticals Inc. | 100 TABLET in 1 BOTTLE (70010-670-01) | January 1, 2022 |
| 70010-670-05 | 70010-670 | Granules Pharmaceuticals Inc. | 500 TABLET in 1 BOTTLE (70010-670-05) | January 1, 2022 |
| 10702-184-01 | 10702-184 | KVK-Tech, Inc. | 100 TABLET in 1 BOTTLE (10702-184-01) | February 9, 2018 |
| 10702-184-10 | 10702-184 | KVK-Tech, Inc. | 1000 TABLET in 1 BOTTLE (10702-184-10) | February 9, 2018 |
| 10702-184-50 | 10702-184 | KVK-Tech, Inc. | 500 TABLET in 1 BOTTLE (10702-184-50) | February 9, 2018 |
| 10702-185-01 | 10702-185 | KVK-Tech, Inc. | 100 TABLET in 1 BOTTLE (10702-185-01) | February 9, 2018 |
| 10702-185-10 | 10702-185 | KVK-Tech, Inc. | 1000 TABLET in 1 BOTTLE (10702-185-10) | February 9, 2018 |
| 10702-185-50 | 10702-185 | KVK-Tech, Inc. | 500 TABLET in 1 BOTTLE (10702-185-50) | February 9, 2018 |
| 10702-186-01 | 10702-186 | KVK-Tech, Inc. | 100 TABLET in 1 BOTTLE (10702-186-01) | February 9, 2018 |
| 10702-186-10 | 10702-186 | KVK-Tech, Inc. | 1000 TABLET in 1 BOTTLE (10702-186-10) | February 9, 2018 |
| 10702-186-50 | 10702-186 | KVK-Tech, Inc. | 500 TABLET in 1 BOTTLE (10702-186-50) | February 9, 2018 |
| 10702-187-01 | 10702-187 | KVK-Tech, Inc. | 100 TABLET in 1 BOTTLE (10702-187-01) | February 9, 2018 |
| 10702-187-10 | 10702-187 | KVK-Tech, Inc. | 1000 TABLET in 1 BOTTLE (10702-187-10) | February 9, 2018 |
| 10702-187-50 | 10702-187 | KVK-Tech, Inc. | 500 TABLET in 1 BOTTLE (10702-187-50) | February 9, 2018 |
| 43386-493-01 | 43386-493 | Lupin Pharmaceuticals,Inc. | 100 TABLET in 1 BOTTLE (43386-493-01) | February 24, 2017 |
| 43386-493-05 | 43386-493 | Lupin Pharmaceuticals,Inc. | 500 TABLET in 1 BOTTLE (43386-493-05) | February 24, 2017 |
| 0904-7093-61 | 0904-7093 | Major Pharmaceuticals | 100 BLISTER PACK in 1 CARTON (0904-7093-61) / 1 TABLET in 1 BLISTER PACK | June 1, 2019 |
| 0904-7094-61 | 0904-7094 | Major Pharmaceuticals | 100 BLISTER PACK in 1 CARTON (0904-7094-61) / 1 TABLET in 1 BLISTER PACK | June 1, 2019 |
| 0904-7095-61 | 0904-7095 | Major Pharmaceuticals | 100 BLISTER PACK in 1 CARTON (0904-7095-61) / 1 TABLET in 1 BLISTER PACK | June 1, 2019 |
| 68071-3683-6 | 68071-3683 | NuCare Pharmaceuticals,Inc. | 6 TABLET in 1 BOTTLE (68071-3683-6) | September 16, 2024 |
| 68071-5054-2 | 68071-5054 | NuCare Pharmaceuticals,Inc. | 12 TABLET in 1 BOTTLE (68071-5054-2) | September 12, 2019 |
| 68071-5054-4 | 68071-5054 | NuCare Pharmaceuticals,Inc. | 4 TABLET in 1 BOTTLE (68071-5054-4) | September 12, 2019 |
| 68071-5054-6 | 68071-5054 | NuCare Pharmaceuticals,Inc. | 6 TABLET in 1 BOTTLE (68071-5054-6) | September 12, 2019 |
| 68071-5169-2 | 68071-5169 | NuCare Pharmaceuticals,Inc. | 20 TABLET in 1 BOTTLE (68071-5169-2) | February 10, 2020 |
| 63187-363-12 | 63187-363 | Proficient Rx LP | 12 TABLET in 1 BOTTLE (63187-363-12) | November 1, 2016 |
| 63187-363-15 | 63187-363 | Proficient Rx LP | 15 TABLET in 1 BOTTLE (63187-363-15) | August 1, 2016 |
| 63187-363-20 | 63187-363 | Proficient Rx LP | 20 TABLET in 1 BOTTLE (63187-363-20) | August 1, 2016 |
| 63187-363-30 | 63187-363 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (63187-363-30) | August 1, 2016 |
| 63187-363-60 | 63187-363 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (63187-363-60) | August 1, 2016 |
| 63187-719-12 | 63187-719 | Proficient Rx LP | 12 TABLET in 1 BOTTLE (63187-719-12) | November 1, 2016 |
| 63187-719-15 | 63187-719 | Proficient Rx LP | 15 TABLET in 1 BOTTLE (63187-719-15) | June 1, 2016 |
| 63187-719-20 | 63187-719 | Proficient Rx LP | 20 TABLET in 1 BOTTLE (63187-719-20) | June 1, 2016 |
| 63187-719-30 | 63187-719 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (63187-719-30) | June 1, 2016 |
| 63187-719-60 | 63187-719 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (63187-719-60) | June 1, 2016 |
| 63187-721-15 | 63187-721 | Proficient Rx LP | 15 TABLET in 1 BOTTLE (63187-721-15) | June 1, 2016 |
| 63187-721-20 | 63187-721 | Proficient Rx LP | 20 TABLET in 1 BOTTLE (63187-721-20) | June 1, 2016 |
| 63187-721-30 | 63187-721 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (63187-721-30) | June 1, 2016 |
| 63187-721-60 | 63187-721 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (63187-721-60) | June 1, 2016 |
| 63187-721-90 | 63187-721 | Proficient Rx LP | 90 TABLET in 1 BOTTLE (63187-721-90) | May 30, 2017 |
| 63187-823-15 | 63187-823 | Proficient Rx LP | 15 TABLET in 1 BOTTLE (63187-823-15) | December 1, 2016 |
| 63187-823-20 | 63187-823 | Proficient Rx LP | 20 TABLET in 1 BOTTLE (63187-823-20) | December 1, 2016 |
| 63187-823-30 | 63187-823 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (63187-823-30) | December 1, 2016 |
| 63187-823-60 | 63187-823 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (63187-823-60) | December 1, 2016 |
| 63187-823-90 | 63187-823 | Proficient Rx LP | 90 TABLET in 1 BOTTLE (63187-823-90) | March 1, 2017 |
| 63187-824-10 | 63187-824 | Proficient Rx LP | 10 TABLET in 1 BOTTLE, PLASTIC (63187-824-10) | December 1, 2017 |
| 63187-824-12 | 63187-824 | Proficient Rx LP | 12 TABLET in 1 BOTTLE, PLASTIC (63187-824-12) | March 1, 2017 |
| 63187-824-15 | 63187-824 | Proficient Rx LP | 15 TABLET in 1 BOTTLE, PLASTIC (63187-824-15) | August 28, 2014 |
| 63187-824-20 | 63187-824 | Proficient Rx LP | 20 TABLET in 1 BOTTLE, PLASTIC (63187-824-20) | August 28, 2014 |
| 63187-824-30 | 63187-824 | Proficient Rx LP | 30 TABLET in 1 BOTTLE, PLASTIC (63187-824-30) | March 1, 2017 |
| 63187-824-60 | 63187-824 | Proficient Rx LP | 60 TABLET in 1 BOTTLE, PLASTIC (63187-824-60) | March 1, 2017 |
| 63187-824-90 | 63187-824 | Proficient Rx LP | 90 TABLET in 1 BOTTLE, PLASTIC (63187-824-90) | March 1, 2017 |
| 63187-984-10 | 63187-984 | Proficient Rx LP | 10 TABLET in 1 BOTTLE (63187-984-10) | February 1, 2018 |
| 63187-984-12 | 63187-984 | Proficient Rx LP | 12 TABLET in 1 BOTTLE (63187-984-12) | February 1, 2018 |
| 63187-984-15 | 63187-984 | Proficient Rx LP | 15 TABLET in 1 BOTTLE (63187-984-15) | February 1, 2018 |
| 63187-984-30 | 63187-984 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (63187-984-30) | February 1, 2018 |
| 63187-984-60 | 63187-984 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (63187-984-60) | February 1, 2018 |
| 71205-329-10 | 71205-329 | Proficient Rx LP | 10 TABLET in 1 BOTTLE (71205-329-10) | December 23, 2019 |
| 71205-329-28 | 71205-329 | Proficient Rx LP | 28 TABLET in 1 BOTTLE (71205-329-28) | August 29, 2022 |
| 71205-329-30 | 71205-329 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (71205-329-30) | September 1, 2019 |
| 71205-329-60 | 71205-329 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (71205-329-60) | September 1, 2019 |
| 71205-329-90 | 71205-329 | Proficient Rx LP | 90 TABLET in 1 BOTTLE (71205-329-90) | September 1, 2019 |
| 71205-347-12 | 71205-347 | Proficient Rx LP | 12 TABLET in 1 BOTTLE (71205-347-12) | November 1, 2019 |
| 71205-347-15 | 71205-347 | Proficient Rx LP | 15 TABLET in 1 BOTTLE (71205-347-15) | November 1, 2019 |
| 71205-347-20 | 71205-347 | Proficient Rx LP | 20 TABLET in 1 BOTTLE (71205-347-20) | November 1, 2019 |
| 71205-347-30 | 71205-347 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (71205-347-30) | November 1, 2019 |
| 71205-347-60 | 71205-347 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (71205-347-60) | November 1, 2019 |
| 71205-347-90 | 71205-347 | Proficient Rx LP | 90 TABLET in 1 BOTTLE (71205-347-90) | November 1, 2019 |
| 71205-486-30 | 71205-486 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (71205-486-30) | October 14, 2020 |
| 71205-486-60 | 71205-486 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (71205-486-60) | October 14, 2020 |
| 71205-486-90 | 71205-486 | Proficient Rx LP | 90 TABLET in 1 BOTTLE (71205-486-90) | October 14, 2020 |
| 49999-852-14 | 49999-852 | Quality Care products LLC | 14 TABLET in 1 BOTTLE, PLASTIC (49999-852-14) | August 10, 2022 |
| 49999-852-30 | 49999-852 | Quality Care products LLC | 30 TABLET in 1 BOTTLE, PLASTIC (49999-852-30) | August 3, 2022 |
| 49999-852-60 | 49999-852 | Quality Care products LLC | 60 TABLET in 1 BOTTLE, PLASTIC (49999-852-60) | August 3, 2022 |
| 49999-852-90 | 49999-852 | Quality Care products LLC | 90 TABLET in 1 BOTTLE, PLASTIC (49999-852-90) | August 3, 2022 |
| 67296-1937-0 | 67296-1937 | RedPharm Drug | 4 TABLET in 1 BOTTLE (67296-1937-0) | August 28, 2014 |
| 67296-1937-1 | 67296-1937 | RedPharm Drug | 10 TABLET in 1 BOTTLE (67296-1937-1) | August 28, 2014 |
| 67296-1937-2 | 67296-1937 | RedPharm Drug | 20 TABLET in 1 BOTTLE (67296-1937-2) | August 28, 2014 |
| 67296-1937-3 | 67296-1937 | RedPharm Drug | 12 TABLET in 1 BOTTLE (67296-1937-3) | August 28, 2014 |
| 67296-1937-6 | 67296-1937 | RedPharm Drug | 6 TABLET in 1 BOTTLE (67296-1937-6) | August 28, 2014 |
| 67296-1937-7 | 67296-1937 | RedPharm Drug | 15 TABLET in 1 BOTTLE (67296-1937-7) | August 28, 2014 |
| 42858-102-01 | 42858-102 | Rhodes Pharmaceuticals LLC | 100 TABLET in 1 BOTTLE, PLASTIC (42858-102-01) | August 28, 2014 |
| 42858-102-10 | 42858-102 | Rhodes Pharmaceuticals LLC | 10 BLISTER PACK in 1 CARTON (42858-102-10) / 10 TABLET in 1 BLISTER PACK | August 28, 2014 |
| 42858-102-50 | 42858-102 | Rhodes Pharmaceuticals LLC | 500 TABLET in 1 BOTTLE, PLASTIC (42858-102-50) | August 28, 2014 |
| 42858-103-01 | 42858-103 | Rhodes Pharmaceuticals LLC | 100 TABLET in 1 BOTTLE, PLASTIC (42858-103-01) | August 28, 2014 |
| 42858-103-10 | 42858-103 | Rhodes Pharmaceuticals LLC | 10 BLISTER PACK in 1 CARTON (42858-103-10) / 10 TABLET in 1 BLISTER PACK | August 28, 2014 |
| 42858-103-50 | 42858-103 | Rhodes Pharmaceuticals LLC | 500 TABLET in 1 BOTTLE, PLASTIC (42858-103-50) | August 28, 2014 |
| 42858-104-01 | 42858-104 | Rhodes Pharmaceuticals LLC | 100 TABLET in 1 BOTTLE, PLASTIC (42858-104-01) | August 28, 2014 |
| 42858-104-10 | 42858-104 | Rhodes Pharmaceuticals LLC | 10 BLISTER PACK in 1 CARTON (42858-104-10) / 10 TABLET in 1 BLISTER PACK | August 28, 2014 |
| 42858-104-50 | 42858-104 | Rhodes Pharmaceuticals LLC | 500 TABLET in 1 BOTTLE, PLASTIC (42858-104-50) | August 28, 2014 |
| 0406-0512-01 | 0406-0512 | SpecGx LLC | 100 TABLET in 1 BOTTLE (0406-0512-01) | December 7, 1983 |
| 0406-0512-05 | 0406-0512 | SpecGx LLC | 500 TABLET in 1 BOTTLE (0406-0512-05) | December 7, 1983 |
| 0406-0512-23 | 0406-0512 | SpecGx LLC | 1 TABLET in 1 BLISTER PACK (0406-0512-23) | December 7, 1983 |
| 0406-0512-62 | 0406-0512 | SpecGx LLC | 100 TABLET in 1 BLISTER PACK (0406-0512-62) | December 7, 1983 |
| 0406-0512-91 | 0406-0512 | SpecGx LLC | 5000 TABLET in 1 PAIL (0406-0512-91) | December 7, 1983 |
| 0406-0522-01 | 0406-0522 | SpecGx LLC | 100 TABLET in 1 BOTTLE (0406-0522-01) | June 30, 2004 |
| 0406-0522-05 | 0406-0522 | SpecGx LLC | 500 TABLET in 1 BOTTLE (0406-0522-05) | June 30, 2004 |
| 0406-0522-23 | 0406-0522 | SpecGx LLC | 1 TABLET in 1 BLISTER PACK (0406-0522-23) | June 30, 2004 |
| 0406-0522-62 | 0406-0522 | SpecGx LLC | 100 TABLET in 1 BLISTER PACK (0406-0522-62) | June 30, 2004 |
| 0406-0523-01 | 0406-0523 | SpecGx LLC | 100 TABLET in 1 BOTTLE (0406-0523-01) | June 30, 2004 |
| 0406-0523-05 | 0406-0523 | SpecGx LLC | 500 TABLET in 1 BOTTLE (0406-0523-05) | June 30, 2004 |
| 0406-0523-23 | 0406-0523 | SpecGx LLC | 1 TABLET in 1 BLISTER PACK (0406-0523-23) | June 30, 2004 |
| 0406-0523-62 | 0406-0523 | SpecGx LLC | 100 TABLET in 1 BLISTER PACK (0406-0523-62) | June 30, 2004 |
| 60760-897-30 | 60760-897 | St. Mary's Medical Park Pharmacy | 30 TABLET in 1 BOTTLE, PLASTIC (60760-897-30) | August 20, 2025 |
| 60760-897-60 | 60760-897 | St. Mary's Medical Park Pharmacy | 60 TABLET in 1 BOTTLE, PLASTIC (60760-897-60) | August 20, 2025 |
| 60760-898-30 | 60760-898 | St. Mary's Medical Park Pharmacy | 30 TABLET in 1 BOTTLE, PLASTIC (60760-898-30) | August 21, 2025 |
| 60760-898-60 | 60760-898 | St. Mary's Medical Park Pharmacy | 60 TABLET in 1 BOTTLE, PLASTIC (60760-898-60) | August 21, 2025 |
| 60760-899-30 | 60760-899 | St. Mary's Medical Park Pharmacy | 30 TABLET in 1 BOTTLE, PLASTIC (60760-899-30) | August 21, 2025 |
| 60760-899-60 | 60760-899 | St. Mary's Medical Park Pharmacy | 60 TABLET in 1 BOTTLE, PLASTIC (60760-899-60) | August 21, 2025 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 12 sections on this page.